Savonix and Fujitsu Connected Technologies Limited Partner to Introduce Savonix Mobile App on Raku-Raku Smartphone F-42A
29.9.2020 14:15:00 EEST | Business Wire | Press release
Savonix, a global leader in digital cognitive health testing, and Fujitsu Connected Technologies Limited (FCNT), one of the major smartphone manufacturers in Japan, unveiled Savonix Mobile–a digital cognitive testing app–on the Raku-Raku Smartphone F-42A.
More than 4.6 million people in Japan are suffering from some form of dementia, with the total expected to soar to about 7.3 million people – or one in five Japanese aged 65 or over – by 2025. Japan’s government last year announced aims to reduce dementia cases by 6 percent in those aged 70 and older over the next six years.
Savonix Mobile, pre-installed on the Raku-Raku Smartphone F-42A, will allow users to test their cognition across eight brain functions such as executive function, working memory, and impulse control. Users will immediately receive test results within the app and will be able to take action to manage their cognitive health. Savonix Mobile detects mild cognitive impairment 93 percent of the time. For this reason, testing cognition is a good way to monitor your brain health over time. Recent studies presented at this year’s Alzheimer’s Association International Conference in July showed that up to 40 percent of dementias may be prevented by changing health habits such as diet, smoking, alcohol use, and sleep. Understanding your lifestyle risks can help you make smarter choices about brain health.
The Raku-Raku Smartphone will also house a pedometer and other important healthcare pre-installed applications to support and manage the user’s health.
“We’re excited about our partnership with FCNT as it will put easy and accurate cognitive testing into the hands of people who need it. This is impactful and aligns with how Japan and Japanese companies like FCNT are leading globally on the prevention of dementia,” said Savonix Founder and CEO Dr. Mylea Charvat. “Our digital cognitive assessment platform enables people to assess and monitor their brain health regularly and to incorporate lifestyle advice to improve brain wellness.”
“It is our great pleasure to have our Raku-Raku Smartphone F-42A equipped with the Savonix Mobile App,” said Katsumi Takada, President & Representative Director at FCNT. “This adoption enables services that support maintaining brain health and reducing the risk of dementia for users. We expect that this will make people more conscious about their health and help them lead a healthier life.”
About Savonix
A global leader in cognitive health, Savonix delivers the only neuropsychology platform in the market. Savonix provides digital cognitive health solutions and empowers healthcare providers, payers, and researchers to evaluate and leverage results to improve health and treatment outcomes. Developed by clinical neuropsychologists and digital health technology experts, the Savonix Cognitive Assessment is an accurate, accessible, and affordable tool available for download on all mobile devices. To learn more about Savonix, visit Savonix.com.
About Fujitsu Connected Technologies
Fujitsu Connected Technologies Limited was established in February 2016 through the spinoff of Fujitsu Limited’s mobile phone business. To create a future where people live their lives fully with peace of mind, FCNT connects people, things, and services in a more comfortable way with transcendental ideas and advanced technologies. FCNT has led the way in its integration of healthcare technologies into mobile phones since they introduced the world's first mobile phone with a pedometer in 2003. For more details, please visit https://www.fujitsu.com/jp/group/fcnt/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200929005016/en/
Contact information
Savonix
Reynald Hiole
+1 415.919.7421
rhiole@savonix.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom